Lifordi Immunotherapeutics Presents Phase 1 Clinical Data for LFD-200, a Subcutaneous Glucocorticoid Antibody Drug Conjugate, at EULAR 2026
Burlington, Massachusetts, June 8, 2026 – Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, presented first-in-human data for LFD-200, the Company’s novel subcutaneously (SC) administered ADC delivering a potent glucocorticoid (GC) directly to immune cells. Phase 1 data from healthy participants (HPs) presented at […] Continue Reading

